光可切换化合物可以通过光在两种异构体之间可逆地切换,继续引起广泛应用的显着关注。偶氮杂芳烃代表了一种相对较新但研究不足的光开关类型,其中传统偶氮苯类中的一个芳环已被五元杂芳环取代。初步研究表明,偶氮杂芳烃——特别是芳基并吡唑——具有优异的光开关特性(定量开关和长 Z 异构体半衰期)。在这里,我们提出了一项系统的计算和实验研究,以阐明芳基并吡唑的长热半衰期和优异的可寻址性的起源,并应用这一理解来确定各种可比较的偶氮杂芳基光开关的重要结构-性质关系。我们通过杂环的调节,鉴定了具有 Z 异构体半衰期从几秒到几小时、到几天甚至几年以及可变吸收特性的化合物。构象可能在决定这些性质方面发挥着最大的作用:异构化半衰期最长的化合物采用 T 形基态 Z 异构体构象并通过 T 形异构化途径进行,而对于具有最长异构化半衰期的化合物,实现了最完整的光开关具有扭曲(而不是 T 形)的 Z 异构体构象。通过平衡这些因素,我们报告了一种新的偶氮吡唑
Influence of ring substituents on the electronic properties of 1,2,4-triazolylidenes
作者:Torsten Hölzel、Christian Ganter
DOI:10.1016/j.jorganchem.2020.121234
日期:2020.6
NHC-precursors. For the nitro compound only a monomethylation to the triazolium salt 3(OTf) is observed. The aminotriazole could be subsequently converted to mono- and dicationic carbene precursors 1I and 2(OTf)2, respectively. The nitrogroup on NHC 3 leads to a decrease of donor strength and a slightly enhanced acceptor character as compared to a related NHC lacking the nitrogroup. The cationic NHC 2
3-氨基-1,2,4-三唑和1-甲基-3-硝基-1,2,4-三唑的甲基化提供了使用三个NHC前体的途径。对于硝基化合物,仅观察到三唑鎓盐3(OTf)的单甲基化。随后可以将氨基三唑分别转化为单和双价卡宾前体1I和2(OTf)2。与缺少硝基的相关NHC相比,NHC 3上的硝基导致供体强度降低,受体特性略有增强。阳离子NHC 2是该系列中最差的供体,显示的TEP值为2072 cm -1。该物种的特性主要由其阳离子性质决定,而NMe 2基团的影响却很小。X射线衍射研究表明NMe 2取代的化合物具有类似胍的性质。
Thiazole-4-carboxyamide derivatives
申请人:Buettelmann Bernd
公开号:US20060160857A1
公开(公告)日:2006-07-20
The present invention is concerned with novel thiazole 4-carboxyamide derivatives of the general formula (I) and with methods for the preparation thereof, which compounds are useful as metabotropic glutamate receptor antagonists:
wherein R
1
to R
4
are as defined in the specification.
Design and Synthesis of Highly Potent and Isoform Selective JNK3 Inhibitors: SAR Studies on Aminopyrazole Derivatives
作者:Ke Zheng、Sarah Iqbal、Pamela Hernandez、HaJeung Park、Philip V. LoGrasso、Yangbo Feng
DOI:10.1021/jm501256y
日期:2014.12.11
expressed primarily in the brain. Numerous reports have shown that inhibition of JNK3 is a promising strategy for treatment of neurodegeneration. The optimization of aminopyrazole-based JNK3 inhibitors with improved potency, isoform selectivity, and pharmacological properties by structure–activity relationship (SAR) studies utilizing biochemical and cell-based assays, and structure-based drug design is reported